Tests whether patients can choose to keep or stop beta blockers in heart failure
Tests a personal trial approach for beta blockers in older adults with heart failure.
Plain-language title generated from the registry record
Registry title: A Preliminary Study for INFORMED
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Weill Cornell MedicineNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- NCT05585125
- Record updated
- 21 August 2026
- Original description
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).Read full original descriptionShow less
A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
Inclusion: Ambulatory adults age ≥ 65 years with HFpEF, according to ACC/AHA guidelines (signs and symptoms of heart failure AND ejection fraction ≥ 50%); Taking beta-blocker.
Exclusion: Other compelling indication(s) for beta-blocker; Prior EF < 50%; Hypertrophic cardiomyopathy; Angina; Acute coronary syndrome, myocardial infarction, or coronary artery bypass surgery in prior 3 years; History of ventricular tachycardia/arrhythmia; Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year; Heart rate >100 bpm within the prior 3 months; Atrial arrhythmia with ventricular rate >90 per minute in the prior 3 months; Systolic blood pressure readings >160 mmHg within the prior 3 months, unless classified as white coat hypertension/effect (and home blood pressures below 140 mmHg); Non-cardiac indications (e.g., migraine prevention, anxiety symptom management, hyperthyroidism, essential tumor reduction); Clinical instability (N-of-1 trials are appropriate for stable conditions only); Decompensated heart failure; Hospitalization in the past 30 days; Medication changes or procedures in the prior 14 days that could confound observations/data at PI discretion; Anticipated medication changes or procedures in subsequent 3 months that could confound observations/data at PI discretion; Clinical instability from other medical issues; Alternate cause(s) of HFpEF Syndrome:; Severe aortic stenosis; Moderate-severe mitral stenosis; Constrictive pericarditis; High output HF; Infiltrative cardiomyopathy; Moderate-severe dementia or psychiatric disorder precluding informed consent; Any condition that, in the Principal Investigator or treating physician's opinion, makes the patient unsuitable for study participation; Estimated life expectancy < 6 months; Language barrier that will preclude informed consent and ability to comprehend study procedures; Non-compliance or inability to complete study procedures; Enrollment in a clinical trial not approved for co-enrollment.